Mereo BioPharma Group plc Issue of Warrants (6372O)
August 22 2017 - 3:17AM
UK Regulatory
TIDMMPH
RNS Number : 6372O
Mereo BioPharma Group plc
22 August 2017
Mereo BioPharma Group plc
("Mereo" or the "Company" or the "Group")
Issue of Warrants
London, 22 August 2017 - Mereo BioPharma Group plc (AIM: MPH), a
clinical stage, UK-based, biopharmaceutical company focused on rare
and specialty diseases, announces that further to the announcement
on 8 August 2017, the Company has issued warrants to Silicon Valley
Bank and Kreos Capital in respect of the right to subscribe for
363,156 shares at the subscription price of 302.9p being the
average of the 10 day mid-market price of the ordinary shares prior
to grant in connection with the debt facility agreed. These
warrants will be capable of exercise from issue until 7 August
2027.
For Further Enquiries:
Mereo BioPharma Group plc +44 (0)333 023 7319
Denise Scots-Knight, Chief
Executive Officer
Richard Jones, Chief Financial
Officer
Nominated Adviser and Joint
Broker
Cantor Fitzgerald Europe +44 (0)20 7894 7000
Phil Davies
Will Goode
Joint Broker
RBC Capital Markets +44 (0)20 7653 4000
Rupert Walford
Laura White
Public Relations Adviser to
Mereo Biopharma
FTI Consulting +44 (0)20 3727 1000
Ben Atwell
Simon Conway
Brett Pollard
US Public Relations Advisor
to Mereo Biopharma +01 (0) 212 213
Burns McClellan 0006
Lisa Burns
Steven Klass
About Mereo
Mereo BioPharma is an innovative biopharma company established
to address the R&D and financial challenges faced by an
increasing number of large pharma and biotech companies. Mereo
focuses on developing and optimizing the value of novel medicines
acquired from large pharma and biotech designed to address
significant unmet medical needs in rare and specialty disease
areas.
Mereo is comprised of a strong team with broad operational
capabilities and the financial resources to conduct comprehensive
clinical studies. The Company plans to build a rare and orphan
commercial business combined with plans to partner where
relevant.
Mereo's initial portfolio consists of three mid-late stage
clinical assets that were acquired from Novartis in July 2015 each
with proof of concept data in the indication that Mereo is now
developing. BPS-804 is being developed for the prevention of
fractures resulting from osteogenesis imperfecta (brittle bone
disease); acumapimod (BCT-197), is being developed to treat
inflammation in patients with an AECOPD; and BGS-649 is a
once-weekly oral novel therapy that restores the patient's own
testosterone in men with hypogonadotropic hypogonadism.
In H1 2016 the Company initiated a Phase 2 study with acumapimod
and a Phase 2b study with BGS-649. Mereo recently announced
commencement of the first potentially pivotal Phase 2b trial for
BPS-804 and completion of enrolment of the acumapimod Phase 2
study. Additional product opportunities, from a range of large
pharmaceutical and biotechnology companies, are under active
evaluation and these are focussed on orphan and rare diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IODGIGDIUBDBGRD
(END) Dow Jones Newswires
August 22, 2017 04:17 ET (08:17 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024